Miodownik Chanoch, Lerner Vladimir, Kibari Adi, Toder Doron, Cohen Hagit
Division of Psychiatry, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
J Clin Psychiatry. 2006 Aug;67(8):1204-8. doi: 10.4088/jcp.v67n0805.
The aims of our study were (1) to compare the dose of clozapine needed to achieve remission in patients who stopped their treatment (study group) versus patients who continued taking this medication (control group) and (2) to compare the clinical characteristics of remission between these 2 groups.
We retrospectively reviewed the medical records of all treatment-resistant schizophrenic and schizoaffective patients (according to DSM-IV criteria) who were treated with clozapine over a period of 9 years, from January 1995 through December 2003. The study group consisted of 43 patients and the control group of 12 patients. All patients' files from both groups were examined, and each patient's remission was scored twice--initially on discharge from the hospital and subsequently after final discharge for the study group, or at the end of the study for the control group.
The change of clozapine dose from the first to the last remission expressed by percentage shows a significant difference between the 43% increase in clozapine dose in the study group and the 12.5% decrease in clozapine dose in the control group (p < .001). Quality of remission assessment showed deterioration in the global remission score in the study group, while the quality of remission assessment in the control group did not show any change.
Our findings suggest that the discontinuation of clozapine treatment leads to a deterioration in the quality of remission, with a need for an increased dose of clozapine. Further prospective studies on larger samples are needed to confirm these findings.
我们研究的目的是:(1)比较停药患者(研究组)与继续服用该药物的患者(对照组)达到缓解所需的氯氮平剂量;(2)比较这两组缓解期的临床特征。
我们回顾性分析了1995年1月至2003年12月期间接受氯氮平治疗的所有难治性精神分裂症和分裂情感性障碍患者(根据DSM-IV标准)的病历。研究组由43例患者组成,对照组由12例患者组成。检查了两组所有患者的病历,每位患者的缓解情况进行了两次评分——研究组最初在出院时评分,随后在最终出院后评分,对照组在研究结束时评分。
从首次缓解到末次缓解氯氮平剂量的变化以百分比表示,研究组氯氮平剂量增加43%与对照组氯氮平剂量减少12.5%之间存在显著差异(p <.001)。缓解评估质量显示研究组整体缓解评分恶化,而对照组的缓解评估质量未显示任何变化。
我们的研究结果表明,停用氯氮平治疗会导致缓解质量恶化,且需要增加氯氮平剂量。需要对更大样本进行进一步的前瞻性研究以证实这些发现。